Skip navigation
Universidade Federal da Bahia |
Repositório Institucional da UFBA
Use este identificador para citar ou linkar para este item: https://repositorio.ufba.br/handle/ri/16014
Registro completo de metadados
Campo DCValorIdioma
dc.contributor.authorMachado, Paulo Roberto Lima-
dc.contributor.authorLessa, Hélio Andrade-
dc.contributor.authorLessa, Marcus-
dc.contributor.authorGuimarães, Luiz H.-
dc.contributor.authorBang, Heejung-
dc.contributor.authorHo, John L.-
dc.contributor.authorCarvalho Filho, Edgar Marcelino de-
dc.creatorMachado, Paulo Roberto Lima-
dc.creatorLessa, Hélio Andrade-
dc.creatorLessa, Marcus-
dc.creatorGuimarães, Luiz H.-
dc.creatorBang, Heejung-
dc.creatorHo, John L.-
dc.creatorCarvalho Filho, Edgar Marcelino de-
dc.date.accessioned2014-09-09T16:15:25Z-
dc.date.issued2007-
dc.identifier.issn1058-4838-
dc.identifier.urihttp://repositorio.ufba.br/ri/handle/ri/16014-
dc.descriptionTexto completo: acesso restrito. p. 788-793pt_BR
dc.description.abstractBackground. Mucosal leishmaniasis is associated with intense tissue damage and high tumor necrosis factor–α production. Therapeutic failure occurs in up to 42% of cases; patients who experience treatment failure will require >1 pentavalent antimony (Sbv) course or alternative drugs to achieve a cure. We previously showed that an inhibitor of tumor necrosis factor–α (pentoxifylline) combined with Sbv cured 90% patients refractory to monotherapy with Sbv. Methods. A double-blind, placebo-controlled trial involving 23 patients with mucosal leishmaniasis evaluated the efficacy of pentoxifylline when administered in association with Sbv, compared with Sbv treatment alone. Eleven patients were randomized to receive Sbv plus oral pentoxifylline for 30 days, and 12 patients received Sbv plus oral placebo. The criterion for cure was a complete healing of lesions. Results. All patients in the pentoxifylline group experienced a cure with 1 course of Sbv, whereas 5 (41.6%) of 12 patients in the placebo group required a second course of Sbv (P = .037). The healing time ± standard deviation in the pentoxifylline group was 83 ± 36 days, compared with 145 ± 99 days in the placebo group (P = .049). No relapses were documented in either group at the 2-year follow-up visit. Conclusions. The addition of pentoxifylline to Sbv in mucosal leishmaniasis reduces the healing time significantly and prevents the need for further courses of Sbv.pt_BR
dc.language.isoenpt_BR
dc.rightsAcesso Abertopt_BR
dc.sourcehttp://dx.doi.org/10.1086/511643pt_BR
dc.titleOral pentoxifylline combined with pentavalent antimony: a randomized trial for mucosal leishmaniasispt_BR
dc.title.alternativeClinical Infectious Diseasespt_BR
dc.typeArtigo de Periódicopt_BR
dc.identifier.numberv. 44, n. 6pt_BR
dc.embargo.liftdate10000-01-01-
Aparece nas coleções:Artigo Publicado em Periódico (Faculdade de Medicina)

Arquivos associados a este item:
Arquivo Descrição TamanhoFormato 
10.1086-511643.pdf145,34 kBAdobe PDFVisualizar/Abrir
Mostrar registro simples do item Visualizar estatísticas


Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.